Strategy and planning for chemopreventive drug development: Clinical development plans II

Journal of Cellular Biochemistry

Volumn 63, Issue SUPPL. 26, 1996, Pages 54-71

  Kelloff, Gary J ^a,b   Crowell, James A ^a,b   Hawk, Ernest T ^a,b   Steele, Vernon E ^a,b   Lubet, Ronald A ^a,b   Boone, Charles W ^a,b   Covey, Joseph M ^a   Doody, Linda A ^b,c   Omenn, Gilbert S ^a,d   Greenwald, Peter ^a   Hong, Waun K ^a,e   Parkinson, David R ^a   Bagheri, Donya ^b   Baxter, Gregory T ^b   Blunden, Margaret ^b   Doeltz, Mary K ^b   Eisenhauer, Karen M ^b   Johnson, Karen ^a   Knapp, Gene G ^a,b   Longfellow, David G ^a   Malone, Winfred F ^a,b   Nayfield, Susan G ^a,b   Seifried, Harold E ^a   Swall, Leah M ^b   Sigman, Caroline C ^a,b,c   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b DCPC   (United States)

^c CCS Associates   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; ALITRETINOIN; CURCUMIN; FOLIC ACID; GENISTEIN; ISOTRETINOIN; PHENETHYL ISOTHIOCYANATE; PRASTERONE; RETINOL; SELENOMETHIONINE; SULINDAC; URSODEOXYCHOLIC ACID; VOROZOLE; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; NONHUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PLANNING; PRIORITY JOURNAL; ANIMAL; CELL TRANSFORMATION; DRUG SCREENING; EXPERIMENTAL NEOPLASM; METHODOLOGY; NEOPLASM; STANDARD;

ANIMALS; ANTICARCINOGENIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL;

EID: 0030325632     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.240630705     Document Type: Article

References (30)

1. Kelloff, G.J., Crowell, J.A., Boone, C.W., Steele, V.E., Lubet, R.A., Greenwald, P., Alberts, D.S., Covey, J.M., Doody, L.A., Knapp, G.G., Nayfield, S., Parkinson, D.R., Prasad, V.K., Prorok, P.C., Sausville, E.A. and Sigman, C.C. Strategy and planning for chemopreventive drug development: Clinical Development Plans. J. Cell. Biochem. 20: 55-299, 1994.
2. Kelloff, G.J., Boone, C.W., Malone, W.F. and Steele, V. Recent results in preclinical and clinical drug development of chemopreventive agents at the National Cancer Institute. In: Wattenberg, L., Lipkin, M., Boone, C.W. and Kelloff, G.J. (eds.) Cancer Chemoprevention. Boca Raton: CRC Press, 1992, pp. 41-56.
3. Kelloff, G.J., Boone, C.W., Crowell, J.A., Steele, V.E., Lubet, R. and Sigman, C.C. Chemopreventive drug development: Perspectives and progress. Cancer Epidemiol. Biomarkers Prev. 3: 85-98, 1994.
4. Kelloff, G.J., Boone, C.W., Steele, V.E., Crowell, J.A., Lubet, R. and Sigman, C.C. Progress in cancer chemoprevention: Perspectives on agent selection and short-term clinical intervention trials. Cancer Res. 54: 2015S-1024S, 1994.
5. Kelloff, G.J., Johnson, J.R., Crowell, J.A., Boone, C.W., DeGeorge, J.J., Steele, V.E., Mehta, M.U., Temeck, J.W., Schmidt, W.J., Burke, G., Greenwald, P. and Temple, R.J. Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol. Biomarkers Prev. 4: 1-10, 1995.
6. Boushey, C.J., Beresford, S.A.A., Omenn, G.S. and Motulsky, A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 274: 1049-1057, 1995.
7. Chanarin, I. Adverse effects of increased dietary folate. Relation to measures to reduce the incidence of neural tube defects. Clin. Invest. Med. 17: 244-252, 1994.
8. Childers, J.M., Chu, J., Voigt, L.F., Feigl, P., Tamimi, H.K., Franklin, B.W., Alberts, D.S. and Meyskens, F.L., Jr. Chemoprevention of cervical cancer with folic acid: A Phase III Southwest Oncology Group Intergroup Study. Cancer Epidemiol. Biomarkers Prev. 4: 155-159, 1995.
9. Whitehead, N., Reyner, F. and Lindenbaum, J. Megaloblastic changes in the cervical epithelium. Association with oral contraceptive therapy and reversal with folic acid. J. Am. Med. Assoc. 226: 1421-1424, 1973.
10. Butterworth, C.E., Jr., Hatch, K.D., Gore, H., Mueller, H. and Krumdieck, C.L. Improvement in cervical dysplasia associated with folic acid therapy in users of oral contraceptives. Am. J. Clin. Nutr. 35: 73-82, 1982.
11. Butterworth, C.E., Jr., Hatch, K.D., Soong, S.J., Cole, P., Tamura, T., Sauberlich, H.E., Borst, M., Macaluso, M. and Baker, V. Oral folic acid supplementation for cervical dysplasia: A clinical intervention trial. Am. J. Obstet. Gynecol. 166: 803-809, 1992.
12. Attili, A.F., Rusticali, A., Varriale, M., Carli, L., Repice, A.M. and Callea, F. The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. A 12-month double-blind, placebo-controlled trial. J. Hepatol. 20: 315-320, 1994.
13. Lim, A.G. and Northfield, T.C. Ursodeoxycholic acid and primary biliary cirrhosis. Br. Med. J. 309: 491-492, 1994.
14. Johnston, S.R.D., Smith, I.E., Doody, D., Jacobs, S., Robenshaw, H. and Dowsett, M. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res. 54: 5875-5881, 1994.
15. Goss, P.E., Clark, R.M., Ambus, U., Weizel, H.A.E., Wadden, N.A., Crump, M., Walde, D., Tye, L.M., De Coster, R. and Bruynseels, J. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. Clin. Cancer Res. 1: 287-294, 1995.
16. Paridaens, R., Piccart, M., Nooy, M., Klijn, J.G.M., Rubens, R.D., Beex, L., Tomiak, E., van Vreckem, J. and Vinholes, J. Phase II study of the EORTC breast group with vorozole (R 83842), a new non-steroidal aromatase inhibitor in metastatic breast cancer (MBC) - Preliminary results. Eur. J. Cancer 29A: S86, abstract no. 455, 1993.
17. Borms, M., Vandebroek, J., Rutten, J., Tytgat, J., De Coster, R., Langenaeken, C. and Bruynseels, J. Vorozole-racemate (R 76713): A specific non-steroidal aromatase inhibitor pilot study in advanced postmenopausal breast cancer. Eur. J. Cancer 29A: S84, abstract no. 442, 1993.
18. Taylor, P.R., Li, B., Dawsey, S.M., Li, J.-Y., Yang, C.S., Guo, W. and Blot, W.J. Prevention of esophageal cancer: The nutrition intervention trials in Linxian, China. Cancer Res. 54: 2029S-1031S, 1994.
19. Blot, W.J., Li, J.-Y., Taylor, P.R., Guo, W., Dawsey, S., Wang, G.-Q., Yang, C.S., Zheng, S.-F., Gail, M., Li, G.-Y., Yu, Y., Liu, B., Tangrea, J., Sun, Y., Liu, F., Fraumeni, J.F., Jr., Zhang, Y.-H. and Li, B. Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J. Natl. Cancer Inst. 85: 1483-1492, 1993.
20. 1 mice (feed studies). NTP Technical Report Series, No. 427, 1993.
21. Kelloff, G.J., Crowell, J.A., Boone, C.W., Steele, V.E., Lubet, R.A., Greenwald, P., Alberts, D.S., Covey, J.M., Doody, L.A., Knapp, G.G., Nayfield, S., Parkinson, D.R., Prasad, V.K., Prorok, P.C., Sausville, E.A. and Sigman, C.C. Clinical Development Plan: Tamoxifen. J. Cell. Biochem. 20: 252-267, 1994.
22. Bradlow, H.L., Michnovicz, J.J., Telang, N.T. and Osborne, M.P. Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 12: 1571-1574, 1991.
23. Kojima, T., Tanaka, T. and Mori, H. Chemoprevention of spontaneous endometrial cancer in female Donryu rats by dietary indole-3-carbinol. Cancer Res. 54: 1446-1449, 1994.
24. Murrill, W.B., Brown, N.M., Zhang, J.-X., Manzolillo, P.A., Barnes, S. and Lamartiniere, C.A. Prepubertal genistein exposure suppresses mammary cancer and enhances gland differentiation in rats. Carcinogenesis 17: 1451-1457, 1996.
25. Brown, N.M. and Lamartiniere, C.A. Xenoestrogens alter mammary gland differentiation and cell proliferation in the rat. Environ. Health Perspect. 103: 708-713, 1995.
26. Shutt, D.A. and Cox, R.I. Steroid and phyto-oestrogen binding to sheep uterine receptors in vitro. J. Endocrinol. 52: 299-310, 1972.
27. Verdeal, K., Brown, R.R., Richardson, T. and Ryan, D.S. Affinity of phytoestrogens for estradiol-binding proteins and effect of coumestrol on growth of 7,12-dimethyl-benz[a]anthracene-induced rat mammary tumors. J. Natl. Cancer Inst. 64: 285-290, 1980.
28. Goodman, G.E. The clinical evaluation of cancer chemoprevention agents: Defining and contrasting phase I, II, and III objectives. Cancer Res. 52: 2752S-2757S, 1992.
29. Hong, W.K., Lippman, S.M., Itri, L.M., Karp, D.D., Lee, J.S., Byers, R.M., Schantz, S.P., Kramer, A.M., Lotan, R., Peters, L.J., Dimery, I.W., Brown, B.W. and Goepfert, H. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 323: 795-801, 1990.
30. Collins, J.M., Grieshaber, C.K. and Chabner, B.A. Pharmacologically guided phase I clinical trials based upon preclinical drug development. J. Natl. Cancer Inst. 82: 1321-1326, 1990.